Genex Pharmaceutical, Inc. engages in the development and production of Reconstituted Bone Xenograft, which is a medical device that accelerates bone healing. The company is headquartered in Tianjin, Tianjin and currently employs 86 full-time employees. The company went IPO on 2006-05-23. The Company’s main business is engaged in producing and distributing Reconstituted Bone Xenograft (RBX). The RBX is a medical device that accelerates bone healing. The firm distributes its medical devices to hospitals as well as other medical device customers that are not hospitals.
Genex Pharmaceutical Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Genex Pharmaceutical Inc en büyük gelir kaynağı Iron Ore Pellets and Concentrate olup, en son kar bildiriminde geliri 689,849,340 dir. Coğrafi olarak, Austria , Genex Pharmaceutical Inc için ana pazar olup, geliri 185,545,242 dir.
Genex Pharmaceutical Inc은 수익성이 있나요?
hayır, 최신 재무제표에 따르면 Genex Pharmaceutical Inc의 순kayıp은 $0입니다.